PDGF and MET pathways, SNAI2, POSTN, COL1A1, ASPN, MUC4, and others may be targets of choice to prevent the evolution of early stage of EMT in HNSCC tumors treated with anti-EGFR therapy. This evidence concerns the gene COL1A1 and head and neck squamous cell carcinoma.